0
Observationa |

A Clinical, Histologic, and Molecular Study of 9 Cases of Congenital Dermatofibrosarcoma Protuberans

Georges Maire, PhD; Sylvie Fraitag, MD; Louise Galmiche, MD; Frédérique Keslair, BSc; Nathalie Ebran, PhD; Marie-José Terrier-Lacombe, MD; Yves de Prost, MD; Florence Pedeutour, PharmD, PhD
[+] Author Affiliations

Author Affiliations: Faculty of Medicine, Laboratory of Solid Tumors Genetics, Nice University Hospital, and Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6543, Nice (Drs Maire, Ebran, and Pedeutour and Mrs Keslair); Departments of Pathology (Drs Fraitag and Galmiche) and Dermatology (Dr de Prost), Necker-Enfants Malades Hospital, Paris; and Department of Pathology, Gustave Roussy Institute, Villejuif (Dr Terrier-Lacombe), France. Dr Maire is now with Princess Margaret Hospital, Ontario Cancer Institute, Toronto.


Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

More Author Information
Arch Dermatol. 2007;143(2):203-210. doi:10.1001/archderm.143.2.203
Text Size: A A A
Published online

Background  The diagnosis of dermatofibrosarcoma protuberans (DFSP) in childhood is often difficult because of the deceptive appearance of the lesions. Little is known about congenital DFSP, the frequency of which is probably underestimated because the initial lesion may pass unnoticed.

Observations  We studied 9 DFSP congenital cases (8 plaques and 1 nodule) initially suspected to be benign lesions. The first biopsies or excisions were performed after a delay of 5½ months to 15 years. All cases were CD34+. Histologic patterns were similar to the DFSP adult classic pattern in 4 cases. One case was a Bednar tumor. The histologic diagnosis of the 4 remaining cases was difficult. The collagen, type I, α 1–platelet-derived growth factor β fusion gene (COL1A1-PDGFB) was detected by means of reverse transcriptase–polymerase chain reaction or fluorescence in situ hybridization.

Conclusions  All cases of congenital DFSP were difficult to identify clinically. The diagnosis was suspected by means of histologic and immunohistochemical evaluation and was confirmed using molecular analyses. This study illustrates the difficulties and pitfalls of the recognition of congenital DFSP and emphasizes the value of immunohistochemical study with anti-CD34 and complementary molecular analysis for all cutaneous spindle cell tumors and plaques in neonates and infants.

Figures in this Article

Dermatofibrosarcoma protuberans (DFSP) is a cutaneous tumor of low-grade malignancy that has long been considered to affect adults almost exclusively. Adult DFSP is usually described as a firm infiltrative protuberant nodule. The histologic pattern of DFSP classically shows dermal and subcutaneous CD34+ spindle-shaped tumor cells arranged in a storiform pattern. Adult DFSP cells show the presence of supernumerary ring chromosomes made up of sequences from chromosomes 17 and 22 that contain the abnormal fusion gene collagen, type I, α 1–platelet-derived growth factor β (COL1A1-PDGFB).1 The detection of COL1A1-PDGFB in giant cell fibroblastomas (GCFs) and Bednar tumors (BTs) demonstrated that DFSP, GCF, and BT share a similar genetic origin and that GCF and BT are morphologic variants of DFSP rather than distinct entities.1 The treatment of choice for patients affected by DFSP or variant tumors (GCF and BT) is surgical excision, by means of Mohs micrographic surgery whenever possible, to ensure tumor-free margins.2 4 Pharmacologic therapy using the tyrosine kinase inhibitor imatinib mesylate is currently under evaluation.5 8

In contrast to adult DFSP, little is known about DFSP in children.9 19 In particular, information about congenital cases is scarce, with only 29 reported.11 12 ,17 ,19 The frequency of DFSP at birth and in childhood is probably underestimated because a significant proportion of patients diagnosed as young adults had an earlier onset. Pediatric DFSP can mimic morphea, atrophic plaques, angiomas, or neurofibromas.10 11 Of the 6 congenital cases described by Weinstein et al,17 none were initially recognized as DFSP. Indeed, these apparently innocuous lesions may be neglected for a long time.10 On presentation, diagnosis is mainly based on the histopathologic evaluation of a biopsy sample or a limited local excision. In cases of small and superficial biopsy samples, pediatric DFSP may be confused with benign neoplasms, such as neurofibroma, fibromatosis, or fibrous hamartoma of infancy. Conversely, it may also mimic histologically aggressive malignant tumors, such as congenital fibrosarcoma.

Even in the case of an unequivocal DFSP histologic pattern, the decision to perform surgery with appropriate margins in infants and young children is always difficult to make because of its potentially mutilating consequences. However, recent results19 of the use of imatinib mesylate in an 18-month-old girl with a large congenital DFSP are encouraging and may open the way to preoperative treatments to reduce the tumor size. Adult and pediatric DFSP share the same molecular anomaly. The COL1A1-PDGFB fusion gene has been detected in 15 of the 16 pediatric cases that have been studied at the molecular level.12 ,15 ,20 26 Our group12 ,27 previously showed the utility of the COL1A1-PDGFB fusion gene detection by means of multiplex reverse transcriptase–polymerase chain reaction (RT-PCR) in fixed paraffin-embedded tissues. Herein, we also performed fluorescence in situ hybridization (FISH) detection of the COL1A1-PDGFB fusion gene in tumor sections. We used FISH and RT-PCR analyses to confirm the diagnosis of DFSP in 9 congenital cases. Most cases were difficult to identify by means of clinical evaluation alone; therefore, the diagnosis was made by histologic evaluation completed by means of molecular and FISH analyses.

Local ethical guidelines were followed for this study. The 9 tumor specimens suspected of being congenital DFSP were referred for molecular analysis to the Laboratory of Solid Tumors Genetics between November 1, 2001, and August 31, 2004. Case 3 was from the Pathology Department of Gustave Roussy Institute, and the other 8 cases were from the Pathology Department of Necker-Enfants Malades Hospital.

HISTOLOGIC AND IMMUNOHISTOCHEMICAL EVALUATION

Tissues were fixed in 10% buffered formalin and paraffin embedded. Five-micrometer sections were stained with hematoxylin-eosin. Immunohistochemical analysis was performed using antibodies against CD34 (QBEnd; Immunotech, Marseille, France) (dilution 1:800), polyclonal S100 protein (Dako, Glostrup, Denmark) (dilution 1:2000), and smooth muscle actin (1A4; Dako) (dilution 1:300). Immunostaining was performed according to the streptavidin-biotin-peroxidase method.28

RNA EXTRACTION AND RT-PCR

RNA extractions, RT-PCR, cloning, and sequencing for detection of the fusion gene COL1A1-PDGFB were performed as previously described.12 ,27 Samples fixed in Bouin fluid were first rinsed in a saturated solution of lithium carbonate and in Tris-EDTA (20mM Tris hydrochloride, pH 8.0; 20mM EDTA, pH 8.0). The amount and quality of the extracted RNA was suitable in 5 cases, including 4 formalin-fixed samples and 1 cultured cell sample. In 4 cases (3 formalin- and 1 Bouin fluid–fixed samples), the RNA was too degraded to be analyzed.

CYTOGENETIC AND FISH ANALYSES

Conventional cytogenetic analysis was performed for cases 1, 3, and 6 according to standard procedures of chromosomal preparations.29 For each case, 15 to 25 metaphase cells were analyzed. The bacterial artificial chromosome (BAC) clones RP11-93L18, RP11-893F2, RP11-959K5, and RP11-642F17 used as probes to detect the COL1A1-PDGFB fusion gene in the FISH experiments have been as described by Craver et al21 (Table 1). The FISH analysis was performed on fixed cell suspensions for cases 1, 3, and 6; on frozen tissue sections for case 1; and on formalin-fixed, paraffin-embedded tissue sections for cases 4, 5, and 7. Five-micrometer-thick sections from frozen or formalin-fixed, paraffin-embedded tissues on glass slides were treated for deproteinization as described by Coindre et al.30 If at least 1 or 2 green fluorescent signals and 1 or 2 red fluorescent signals per cell could not be seen in at least 80% of cells, the result was considered to be noninterpretable (failure of the hybridization generally due to inappropriate deproteinization conditions). For each analyzed nucleus, we evaluated the presence or absence of at least 1 yellow (or closely juxtaposed red-green) signal, resulting from fusion of the red and green fluorescent signals corresponding to the COL1A1 and PDGFB loci.

Table Grahic Jump LocationTable 1. Description and Origin of the BAC Clones Used as Probes to Detect the COL1A1-PDGFB Fusion Gene by Means of FISH Analysis
CLINICAL FINDINGS

Clinical data from the 9 patients are given in Table 2. There were 6 girls and 3 boys. The first biopsies or excisions were performed at ages varying from 5½ months to 15 years. Four lesions were located on the trunk. Other locations were the head, foot, buttock, and thigh. In 8 cases, the lesions were described as plaques (Figures 1, 2, and 3), whereas 1 lesion was a subcutaneous lump (case 8). In all cases except 1, the lesion was larger than 4 cm. The clinical evolution of the lesions consisted of very slow enlargement in cases 3, 5, and 6 and the appearance of nodules in cases 4, 6, and 7. All the tumors except 1 (case 6) were surgically treated by means of limited or wide excision. Tumors with positive margins were subjected to reexcision (cases 4, 7, and 8). Case 3 was the only case of the series suspected to be DFSP at the first clinical examination (at 11 years old). A hypopigmented plaque was present already at birth, but medical counseling was sought only after considerable enlargement at 11 years old (Figure 1). Clinical diagnoses in the other cases were difficult and erratic, probably because the lesions were examined at a young patient age, when they still did not have a fully typical appearance of DFSP. In cases manifesting as plaques, benign lesions such as tufted hemangioma, angioma, fibrous hamartoma of infancy, infantile fibromatosis, congenital cutaneous aplasia, mastocytoma, and sacrococcygeal teratoma were initially suspected (Table 2). In case 5, a very small bluish plaque remained difficult to characterize clinically. For the erythematous and infiltrating plaque of case 2, no precise clinical diagnosis was established. In cases 7 and 8, which had the appearance of an erythematous macule and a subcutaneous bluish lump, respectively, a fibrosarcoma was proposed among the possible diagnoses.

Place holder to copy figure label and caption
Figure 1.

Case 3. A, Small nodules arising on a hypopigmented congenital plaque on the back of an 11-year-old boy. B, A characteristic histologic dermatofibrosarcoma protuberans pattern (hematoxylin-eosin, original magnification ×200). C, Partial RHG tumor cell karyotype showing 2 normal chromosomes 17 and 1 chromosome 22. Arrows indicate 2 abnormal chromosomes 22 derived from an unbalanced t(17;22). D, Interphase fluorescence in situ hybridization. Arrows indicate the merged green-red signal corresponding to the collagen, type I, α 1–platelet-derived growth factor β (COL1A1-PDGFB) fusion gene on the 2 abnormal chromosomes 22. The individual green and red signals correspond to COL1A1 on the 2 normal chromosomes 17 and PDGFB on the normal chromosome 22. E, Sequence of the COL1A1-PDGFB fusion gene detected by means of reverse transcriptase–polymerase chain reaction, showing an in-frame fusion of COL1A1 exon 48 (bold) with PDGFB exon 2.

Grahic Jump Location
Place holder to copy figure label and caption
Figure 2.

Case 4. A, Pinkish plaque with 6 cm of alopecia. The lesion was firm and fibrous. B, Thin biopsy specimen of the recurrence revealed the presence of a discrete proliferation of regular spindle-shaped cells in the deep dermis. Cellular density is slight and is associated with an abundant collagen matrix (hematoxylin-eosin, original magnification ×25). C, Strong and diffuse expression of CD34 by tumor cells (labeling with anti-CA34 antibody, original magnification ×25). D, Fluorescence in situ hybridization analysis on formalin-fixed, paraffin-embedded sections from the biopsy sample. Arrow indicates the merged green-red signal corresponding to the collagen, type I, α 1–platelet-derived growth factor β (COL1A1-PDGFB) fusion gene in a tumor cell nucleus (hematoxylin-eosin, original magnification ×100). E, Sequence of the COL1A1-PDGFB fusion gene detected by means of reverse transcriptase–polymerase chain reaction, showing an in-frame fusion of COL1A exon 32 (bold) with PDGFB exon 2. Total RNA was extracted from the formalin-fixed, paraffin-embedded biopsy fragment.

Grahic Jump Location
Place holder to copy figure label and caption
Figure 3.

Case 6. Dermatofibrosarcoma protuberans with peculiar histologic features. A, Indurated angiomatous plaque of the limb. B, Typical spindle cell proliferation in the subcutis (these spindle cells were positive when labeled with anti–CD34 antibodies [not shown]) (hematoxylin-eosin, original magnification ×100). C, Nodules of round cells in the deep dermis surrounding numerous capillaries (hematoxylin-eosin, original magnification ×100). D, Fluorescence in situ hybridization on dissociated cells from the biopsy sample showed separate green (collagen, type I, α 1 [COL1A1] probe) and red (platelet-derived growth factor β polypeptide [PDGFB] probe) signals on a cell nucleus. This pattern of signals demonstrates the absence of the COL1A1-PDGFB rearrangement.

Grahic Jump Location
Table Grahic Jump LocationTable 2. Clinical and Histologic Data From 9 Congenital Lesions
HISTOLOGIC AND MOLECULAR FINDINGS
DFSP With Classic Histologic Patterns

Cases 3, 5, 7, and 8 had histologic features similar to the adult classic pattern of DFSP (Table 2). The epidermis was normal or slightly thinned. The dermis and the subcutaneous fat showed a dense, poorly circumscribed, monomorphous cell proliferative mass arranged in interwoven fascicles with a typical “honeycomb” pattern (Figure 1). Proliferating cells were CD34+, PS100 negative, SMA negative, and spindle shaped and did not show any atypia.

Necrotic, fibrosarcomatous, and mitotic areas were absent. Case 7 was initially diagnosed as a desmoid fibromatosis because at the time of excision DFSP was not yet considered to be a tumor that affects children; moreover, anti–CD34 antibody was not available. The diagnosis was later revised to DFSP on the basis of the CD34+ labeling and the COL1A1-PDGFB fusion gene detected by means of FISH. Case 9 presented as typical CD34+ DFSP containing pigmented neoplastic cells and was diagnosed as a BT. The COL1A1-PDGFB fusion gene was detected by FISH or RT-PCR in cases 3, 5, and 7 (Table 3 and Figure 1). The fusion genes identified by means of RT-PCR in cases 3 and 5 involved COL1A1 exons 46 and 48, respectively (Table 3), and merged FISH signals corresponding to the fusion of COL1A1 with PDGFB probes were observed in cases 3, 5, and 7 (Figure 1). The tumor karyotype of case 3 was abnormal, showing an unbalanced t(17;22) translocation (Figure 1): 47,XY,+der(22)t(17;22)(q22;q13.1)[1]/47,XY,der(22)t(17;22)(q22;q13.1),+der(22)t(17;22)(q22;q13.1)[1]/46,XY[13]. No molecular or FISH result was obtained for cases 8 and 9.

Table Grahic Jump LocationTable 3. Molecular Detection of the COL1A1-PDGFB Fusion Gene by Means of RT-PCR and FISH in 9 Congenital DFSP Cases
DFSP With Peculiar Histologic Features

Cases 1, 2, 4, and 6 had some histologic features evocative of DFSP but also presented unusual features that made the diagnosis difficult. However, infiltration and immunohistochemical patterns as well as molecular data confirmed the diagnosis of DFSP. In cases 1, 2, and 4, histologic examination of early biopsy samples showed loose, dermal, monomorphic, spindle-shaped cell proliferation, sparing adnexal structures and extending to the upper subcutis (Figure 2 and Figure 4). In the subcutis, cell proliferation was arranged in interstitial bundles and was associated with interspersed mature fat. Tumor cells occasionally showed a vacuolated lipoblastlike light cytoplasm.

Place holder to copy figure label and caption
Figure 4.

Case 2. Dermatofibrosarcoma protuberans with peculiar histologic features. Loose dermal proliferation badly limited and extending in the upper subcutis (hematoxylin-eosin, original magnification ×25).

Grahic Jump Location

Cellular density was very low, without nuclear atypia, mitoses, or storiform pattern. There were always moderately dilated blood vessels, with thick hyaline walls. All the cases were CD34+, PS100 negative, and SMA negative. Initial diagnoses of fibrous hamartoma of infancy, angioma, and lipoblastoma were often discussed before the results of the immunohistochemical study were known. Diagnosis of DFSP was established using RT-PCR and FISH analyses (fusion of the COL1A1 exon 32 with the PDGFB exon 2) for case 4 (Figure 2). For cases 1 and 2, the COL1A1-PDGFB fusion gene was detected by means of FISH analysis (RT-PCR could not be performed because of lack of good-quality RNA). Case 6 showed a combination of typical CD34+ spindle cells and dermal plump cells packed in small nodules surrounding numerous capillaries that did not express CD34 (Figure 3). No COL1A1-PDGFB fusion gene was detected by means of RT-PCR and FISH, and the tumor karyotype did not show any chromosomal abnormality (Figure 3).

We report a series of 9 congenital lesions that illustrate the difficulties and pitfalls of the recognition and diagnosis of childhood DFSP and highlight the benefit of immunohistochemical and molecular investigations. The most frequent anatomical locations in this series were the trunk (4 of 9 cases) and the proximal extremities (2 of 9 cases). This is consistent with locations previously reported in most congenital DFSP.17 The trunk and proximal extremities are also the most frequent sites for adult DFSP. However, as stressed by Weinstein et al,17 a clinical suggestion of congenital DFSP should not be ruled out because of a lower limb or head location, and pediatric DFSP may occur frequently in distal acral locations.12 All the lesions except 1 had a nonnodular clinical appearance, which was described. They were depicted using various terms, such as erythematous, pinkish, bluish, hypopigmented, angiomatous, depressed, atrophic, fibrous, infiltrated, or firm plaques, or as erythematous macules.

We noticed a significant delay (5½ months to 15 years) between onset of the lesion and proper diagnosis. In some cases it was due to the innocuous appearance of the plaque, which did not prompt the parents to seek medical advice or the physician to perform a biopsy. In other cases, the delay was caused by an erroneous initial histologic diagnosis. This was the case for biopsies performed before 1995, which is before anti-CD34 labeling, which is now a powerful diagnostic tool for distinguishing DFSP from other tumors. In most cases, the initial clinical diagnoses were more often directed toward nonneoplastic or benign lesions, such as congenital cutaneous aplasia, hematoma, infantile fibromatosis, myofibromatosis, hamartoma, hemangioma, tufted angioma, mastocytoma, and teratoma.

In most cases, diagnoses were made on the basis of classic histologic and immunohistochemical features. Histologic recognition was particularly difficult because of the very small size of the skin biopsy samples, which usually ranged from 2 to 3 mm. These tiny biopsy samples did not allow a proper overview of the various aspects of the tumor. In particular, they were sometimes too superficial to include the “honeycomb” pattern and the high cellular density of the hypodermal infiltration. Moreover, the histologic patterns were sometimes misleading. We noted that lesions that were histologically typical of DFSP were in older children vs biopsy samples with difficult-to-interpret histologic features. Thus, the confusing histologic appearance of some of the samples may be related to the very early stage of the lesions. For example, the tissue lacked hypercellularity or a storiform pattern and instead had loosely and angiomatous stroma, plexiform arrangements, and even lipoblastlike tumoral cells. CD34 immunohistochemical positivity along with PS100 and SMA negativity was a relevant and crucial element of diagnosis by means of biopsy or excision. These tests helped to eliminate improper diagnoses, such as juvenile fibromatosis, infantile fibrosarcoma, and fibrous hamartoma of infancy. However, a CD34+ spindle cell proliferation of the reticular dermis does not always indicate a DFSP because a new entity called “dermal dendrocyte hamartoma” has recently been described in infancy.31 This entity can be confused with DFSP and can be distinguished by the absence of COL1A1-PDGFB rearrangement. At the histologic level, 1 case of congenital plaque was a BT. To our knowledge, this is the first description of a congenital BT among the 12 cases of BT reported in children.15 16

Genetic investigations provide a powerful complementary tool for the diagnosis of DFSP. In this study, we performed conventional cytogenetic analysis of 3 cases. In 2 cases, the results were not informative because no chromosomal abnormality was detected. A normal karyotype may indeed represent the growth of stromal fibroblasts instead of tumor cells. In the other case, we observed an unbalanced t(17;22) translocation. This confirms that the cytogenetic hallmark of pediatric DFSP, GCF, and BT is a translocation and not a ring chromosome as in adults.1 It remains unresolved whether pediatric translocation derivative chromosomes undergo a transformation into ring chromosomes when the patient grows up and whether this transformation might be associated with the progression from plaque to nodular form. The presence of the COL1A1-PDGFB fusion gene specific to DFSP and variant tumors can be detected by means of RT-PCR and FISH (F.P., unpublished data, 2002-2006).1 We performed RT-PCR–based detection of the COL1A1-PDGFB fusion gene in 5 of the 9 lesions. The COL1A1-PDGFB fusion gene was detected in 3 cases, with breakpoints in COL1A1 exons 32, 46, and 48. These breakpoints have also been described in pediatric and adult DFSP.1 These data confirm the lack of a preferential COL1A1 breakpoint location correlating with the age of the patient, the histologic subtype, or any clinical particularity. In these 3 cases, the fusion gene was also detected by means of FISH analysis. The FISH analysis was also useful to identify the COL1A1-PDGFB fusion in 2 cases for which no RNA of sufficient quality could be obtained. In the 2 negative cases it is not known whether the negative results were because of lack of sensitivity of the RT-PCR and FISH methods or because of the real absence of the COL1A1-PDGFB fusion gene. The absence of COL1A1-PDGFB may suggest a diagnosis of a lesion other than a DFSP. However, it has to be noticed that a small proportion of DFSP, estimated to be approximately 5% of cases, may contain gene rearrangements other than the classic COL1A1-PDGFB fusion.1 Herein, the diagnosis was finally made on the basis of the morphologic and immunohistologic pattern, although case 6 had some unusual features, such as the presence of foci of round cells.

These results in a series of congenital tumors indicate that the chromosomal rearrangements in these cases took place during pregnancy. Mechanisms of neoplasm formation in utero are still obscure.32 37 It can be hypothesized that illegitimate recombination between COL1A1 and PDGFB sequences might arise during embryogenesis or fetal development and lead to DFSP formation. To date, there are no epidemiologic data that identify any environmental or predisposing factors that may induce the development of prenatal DFSP. This warrants further investigation and could be facilitated by a systematic questionnaire about medical antecedents and maternal exposure in pediatric DFSP cases.

In conclusion, these data show that congenital forms of DFSP are often clinically misleading and that it is important to perform a biopsy on suspicious cutaneous lesions in infants. When a DFSP is histologically identified or suspected, COL1A1-PDGFB fusion gene detection will complete the investigations. From this experience, the multiplex RT-PCR analysis is useful for retrospective studies or to confirm a doubtful FISH result, but it is not the most appropriate method for routine diagnosis. In our hands, the method of choice for daily practice is FISH analysis. Fluorescence in situ hybridization on fresh or frozen samples allows better image resolution than FISH on paraffin-embedded samples; however, from a practical point of view, paraffin-embedded samples are easier to handle than frozen tissues. We recommend that a molecular analysis should be performed in any case of DFSP suspicion, preferably by means of FISH, otherwise by means of RT-PCR on paraffin-embedded samples, before performing large, often mutilating, surgical excision in infants.

Correspondence: Florence Pedeutour, PharmD, PhD, Laboratoire de Génétique des tumeurs Solides, Faculté de Médecine, 28 avenue de Valombrose, 06107 Nice CEDEX 2, France (florence.pedeutour@unice.fr).

Financial Disclosure: None reported.

Accepted for Publication: July 18, 2006.

Author Contributions: Dr Pedeutour had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Maire, Fraitag, de Prost, and Pedeutour. Acquisition of data: Maire, Fraitag, Galmiche, Keslair, Ebran, Terrier-Lacombe, de Prost, and Pedeutour. Analysis and interpretation of data: Maire, Fraitag, Galmiche, and Pedeutour. Drafting of the manuscript: Maire, Fraitag, Galmiche, Keslair, Ebran, and Pedeutour. Critical revision of the manuscript for important intellectual content: Maire, Fraitag, de Prost, and Pedeutour. Statistical analysis: Fraitag and Galmiche. Obtained funding: Fraitag, de Prost, and Pedeutour. Administrative, technical, and material support: Maire, Fraitag, Keslair, Ebran, and Pedeutour. Study supervision: Fraitag, de Prost, and Pedeutour.

Funding/Support: This work was supported by ARC grant 3386 from the Association pour la Recherche sur le Cancer (Dr Pedeutour), The Programme Hospitalier de Recherche Clinique National 2003, The Ligue Nationale Contre le Cancer, Comité des Alpes-Maritimes, and the Cancéropôle Provence Alpes-Côte d’Azur.

Acknowledgment: We thank Mariano Rocchi, PhD (Resources for Molecular Cytogenetics, University of Bari, Bari, Italy), for the gift of BAC clone RP11-893F2, Karen L. Huyck, MD, PhD, for editing the manuscript, and Agnès Carlotti, MD (Hôpital Tarnier, Paris), Jean Francois Stalder, MD (CHU Nantes, France), Gerard Lorette, MD (CHU Tours, France), Dominique Hamel-Teillac, MD, Christine Bodemer, MD, PhD, Jean Claude Amoric, MD, Philippe Delanoé, MD (GHU ouest, Hôpital Necker-Enfants Malades), and Jacqueline Chevrant-Breton, MD (CHU Rennes, France), for providing histologic samples and clinical data.

Sirvent  N, Maire  G, Pedeutour  F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003;371- 19
PubMed
Ratner  D, Thomas  CO, Johnson  TM.  et al.  Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37600- 613
PubMed
DuBay  D, Cimmino  V, Lowe  L, Johnson  TM, Sondak  VK. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004;1001008- 1016
PubMed
Huether  MJ, Zitelli  JA, Brodland  DG. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol 2001;44656- 659
PubMed
Maki  RG, Awan  RA, Dixon  RH, Jhanwar  S, Antonescu  CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100623- 626
PubMed
Rubin  BP, Schuetze  SM, Eary  JF.  et al.  Molecular targeting of platelet-derived growth factor β by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;203586- 3591
PubMed
Mizutani  K, Tamada  Y, Hara  K.  et al.  Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004;151235- 237
PubMed
McArthur  GA, Demetri  GD, van Oosterom  A.  et al.  Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23866- 873
PubMed
Pappo  AS, Rao  BN, Cain  A, Bodner  S, Pratt  CB. Dermatofibrosarcoma protuberans: the pediatric experience at St. Jude Children's Research Hospital. Pediatr Hematol Oncol 1997;14563- 568
PubMed
Martin  L, Combemale  P, Dupin  M.  et al.  The atrophic variant of dermatofibrosarcoma protuberans in childhood: a report of six cases. Br J Dermatol 1998;139719- 725
PubMed
Checketts  SR, Hamilton  TK, Baughman  RD. Congenital and childhood dermatofibrosarcoma protuberans: a case report and review of the literature. J Am Acad Dermatol 2000;42907- 913
PubMed
Terrier-Lacombe  MJ, Guillou  L, Maire  G.  et al.  Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003;2727- 39
PubMed
Marcus  JR, Few  JW, Senger  C, Reynolds  M. Dermatofibrosarcoma protuberans and the Bednar tumor: treatment in the pediatric population. J Pediatr Surg 1998;331811- 1814
PubMed
Marini  M, Saponaro  A, Magarinos  G, de Baldrich  A, Lynch  P, Remorino  L. Congenital atrophic dermatofibrosarcoma protuberans. Int J Dermatol 2001;40448- 450
PubMed
Maire  G, Martin  L, Michalak-Provost  S.  et al.  Fusion of COL1A1 exon 29 with PDGFB exon 2 in a der(22)t(17;22) in a pediatric giant cell fibroblastoma with a pigmented Bednar tumor component: evidence for age-related chromosomal pattern in dermatofibrosarcoma protuberans and related tumors. Cancer Genet Cytogenet 2002;134156- 161
PubMed
Reis-Filho  JS, Milanezi  F, Ferro  J, Schmitt  FC. Pediatric pigmented dermatofibrosarcoma protuberans (Bednar tumor): case report and review of the literature with emphasis on the differential diagnosis. Pathol Res Pract 2002;198621- 626
PubMed
Weinstein  JM, Drolet  BA, Esterly  NB.  et al.  Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 2003;139207- 211
PubMed
Thornton  SL, Reid  J, Papay  FA, Vidimos  AT. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol 2005;5376- 83
PubMed
Price  VE, Fletcher  JA, Zielenska  M.  et al.  Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005;44511- 515
PubMed
Simon  MP, Pedeutour  F, Sirvent  N.  et al.  Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997;1595- 98
PubMed
Craver  R, Dewenter  T, Ebran  N, Pedeutour  F. COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of der(17;22). Cancer Genet Cytogenet 2006;168155- 157
PubMed
O'Brien  KP, Seroussi  E, Dal Cin  P.  et al.  Various regions within the α-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998;23187- 193
PubMed
Wang  J, Hisaoka  M, Shimajiri  S, Morimitsu  Y, Hashimoto  H. Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription-polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 1999;8113- 119
PubMed
Wang  J, Morimitsu  Y, Okamoto  S.  et al.  COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans. J Mol Diagn 2000;247- 52
PubMed
Gokden  N, Dehner  LP, Zhu  X, Pfeifer  JD. Dermatofibrosarcoma protuberans of the vulva and groin: detection of COL1A1-PDGFB fusion transcripts by RT-PCR. J Cutan Pathol 2003;30190- 195
PubMed
Saeki  H, Ohmatsu  H, Hoashi  T.  et al.  Dermatofibrosarcoma protuberans with COL1A1 (exon 18)-PDGFB (exon 2) fusion transcript. Br J Dermatol 2003;1481028- 1031
PubMed
Maire  G, Pedeutour  F, Coindre  JM. COL1A1-PDGFB gene fusion demonstrates a common histogenetic origin for dermatofibrosarcoma protuberans and its granular cell variant. Am J Surg Pathol 2002;26932- 937
PubMed
Hsu  SM, Raine  L. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibodies (PAP) procedures. J Histochem Cytochem 1981;29577- 580
PubMed
Limon  J, Dal Cin  P, Sandberg  AA. Application of long-term collagenase disaggregation for the cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet 1986;23305- 313
PubMed
Coindre  JM, Hostein  I, Maire  G.  et al.  Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 2004;203822- 830
PubMed
Rodriguez-Jurado  R, Palacios  C, Duran-McKinster  C.  et al.  Medallion-like dermal dendrocyte hamartoma: a new clinically and histopathologically distinct lesion. J Am Acad Dermatol 2004;51359- 363
PubMed
Ford  AM, Ridge  SA, Cabrera  ME.  et al.  In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993;363358- 360
PubMed
Ford  AM, Pombo-de-Oliveira  MS, McCarthy  KP.  et al.  Monoclonal origin of concordant T-cell malignancy in identical twins. Blood 1997;89281- 285
PubMed
Ford  AM, Bennett  CA, Price  CM, Bruin  MC, Van Wering  ER, Greaves  M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S A 1998;954584- 4588
PubMed
Gale  KB, Ford  AM, Repp  R.  et al.  Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997;9413950- 13954
PubMed
Alexander  FE, Patheal  SL, Biondi  A.  et al.  Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001;612542- 2546
PubMed
Lightfoot  TJ, Roman  E. Causes of childhood leukaemia and lymphoma. Toxicol Appl Pharmacol 2004;199104- 117
PubMed

First Page Preview

First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.

Case 3. A, Small nodules arising on a hypopigmented congenital plaque on the back of an 11-year-old boy. B, A characteristic histologic dermatofibrosarcoma protuberans pattern (hematoxylin-eosin, original magnification ×200). C, Partial RHG tumor cell karyotype showing 2 normal chromosomes 17 and 1 chromosome 22. Arrows indicate 2 abnormal chromosomes 22 derived from an unbalanced t(17;22). D, Interphase fluorescence in situ hybridization. Arrows indicate the merged green-red signal corresponding to the collagen, type I, α 1–platelet-derived growth factor β (COL1A1-PDGFB) fusion gene on the 2 abnormal chromosomes 22. The individual green and red signals correspond to COL1A1 on the 2 normal chromosomes 17 and PDGFB on the normal chromosome 22. E, Sequence of the COL1A1-PDGFB fusion gene detected by means of reverse transcriptase–polymerase chain reaction, showing an in-frame fusion of COL1A1 exon 48 (bold) with PDGFB exon 2.

Grahic Jump Location
Place holder to copy figure label and caption
Figure 2.

Case 4. A, Pinkish plaque with 6 cm of alopecia. The lesion was firm and fibrous. B, Thin biopsy specimen of the recurrence revealed the presence of a discrete proliferation of regular spindle-shaped cells in the deep dermis. Cellular density is slight and is associated with an abundant collagen matrix (hematoxylin-eosin, original magnification ×25). C, Strong and diffuse expression of CD34 by tumor cells (labeling with anti-CA34 antibody, original magnification ×25). D, Fluorescence in situ hybridization analysis on formalin-fixed, paraffin-embedded sections from the biopsy sample. Arrow indicates the merged green-red signal corresponding to the collagen, type I, α 1–platelet-derived growth factor β (COL1A1-PDGFB) fusion gene in a tumor cell nucleus (hematoxylin-eosin, original magnification ×100). E, Sequence of the COL1A1-PDGFB fusion gene detected by means of reverse transcriptase–polymerase chain reaction, showing an in-frame fusion of COL1A exon 32 (bold) with PDGFB exon 2. Total RNA was extracted from the formalin-fixed, paraffin-embedded biopsy fragment.

Grahic Jump Location
Place holder to copy figure label and caption
Figure 3.

Case 6. Dermatofibrosarcoma protuberans with peculiar histologic features. A, Indurated angiomatous plaque of the limb. B, Typical spindle cell proliferation in the subcutis (these spindle cells were positive when labeled with anti–CD34 antibodies [not shown]) (hematoxylin-eosin, original magnification ×100). C, Nodules of round cells in the deep dermis surrounding numerous capillaries (hematoxylin-eosin, original magnification ×100). D, Fluorescence in situ hybridization on dissociated cells from the biopsy sample showed separate green (collagen, type I, α 1 [COL1A1] probe) and red (platelet-derived growth factor β polypeptide [PDGFB] probe) signals on a cell nucleus. This pattern of signals demonstrates the absence of the COL1A1-PDGFB rearrangement.

Grahic Jump Location
Place holder to copy figure label and caption
Figure 4.

Case 2. Dermatofibrosarcoma protuberans with peculiar histologic features. Loose dermal proliferation badly limited and extending in the upper subcutis (hematoxylin-eosin, original magnification ×25).

Grahic Jump Location

Tables

Table Grahic Jump LocationTable 1. Description and Origin of the BAC Clones Used as Probes to Detect the COL1A1-PDGFB Fusion Gene by Means of FISH Analysis
Table Grahic Jump LocationTable 2. Clinical and Histologic Data From 9 Congenital Lesions
Table Grahic Jump LocationTable 3. Molecular Detection of the COL1A1-PDGFB Fusion Gene by Means of RT-PCR and FISH in 9 Congenital DFSP Cases

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Sirvent  N, Maire  G, Pedeutour  F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003;371- 19
PubMed
Ratner  D, Thomas  CO, Johnson  TM.  et al.  Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37600- 613
PubMed
DuBay  D, Cimmino  V, Lowe  L, Johnson  TM, Sondak  VK. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004;1001008- 1016
PubMed
Huether  MJ, Zitelli  JA, Brodland  DG. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol 2001;44656- 659
PubMed
Maki  RG, Awan  RA, Dixon  RH, Jhanwar  S, Antonescu  CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100623- 626
PubMed
Rubin  BP, Schuetze  SM, Eary  JF.  et al.  Molecular targeting of platelet-derived growth factor β by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;203586- 3591
PubMed
Mizutani  K, Tamada  Y, Hara  K.  et al.  Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004;151235- 237
PubMed
McArthur  GA, Demetri  GD, van Oosterom  A.  et al.  Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23866- 873
PubMed
Pappo  AS, Rao  BN, Cain  A, Bodner  S, Pratt  CB. Dermatofibrosarcoma protuberans: the pediatric experience at St. Jude Children's Research Hospital. Pediatr Hematol Oncol 1997;14563- 568
PubMed
Martin  L, Combemale  P, Dupin  M.  et al.  The atrophic variant of dermatofibrosarcoma protuberans in childhood: a report of six cases. Br J Dermatol 1998;139719- 725
PubMed
Checketts  SR, Hamilton  TK, Baughman  RD. Congenital and childhood dermatofibrosarcoma protuberans: a case report and review of the literature. J Am Acad Dermatol 2000;42907- 913
PubMed
Terrier-Lacombe  MJ, Guillou  L, Maire  G.  et al.  Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003;2727- 39
PubMed
Marcus  JR, Few  JW, Senger  C, Reynolds  M. Dermatofibrosarcoma protuberans and the Bednar tumor: treatment in the pediatric population. J Pediatr Surg 1998;331811- 1814
PubMed
Marini  M, Saponaro  A, Magarinos  G, de Baldrich  A, Lynch  P, Remorino  L. Congenital atrophic dermatofibrosarcoma protuberans. Int J Dermatol 2001;40448- 450
PubMed
Maire  G, Martin  L, Michalak-Provost  S.  et al.  Fusion of COL1A1 exon 29 with PDGFB exon 2 in a der(22)t(17;22) in a pediatric giant cell fibroblastoma with a pigmented Bednar tumor component: evidence for age-related chromosomal pattern in dermatofibrosarcoma protuberans and related tumors. Cancer Genet Cytogenet 2002;134156- 161
PubMed
Reis-Filho  JS, Milanezi  F, Ferro  J, Schmitt  FC. Pediatric pigmented dermatofibrosarcoma protuberans (Bednar tumor): case report and review of the literature with emphasis on the differential diagnosis. Pathol Res Pract 2002;198621- 626
PubMed
Weinstein  JM, Drolet  BA, Esterly  NB.  et al.  Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 2003;139207- 211
PubMed
Thornton  SL, Reid  J, Papay  FA, Vidimos  AT. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol 2005;5376- 83
PubMed
Price  VE, Fletcher  JA, Zielenska  M.  et al.  Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005;44511- 515
PubMed
Simon  MP, Pedeutour  F, Sirvent  N.  et al.  Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997;1595- 98
PubMed
Craver  R, Dewenter  T, Ebran  N, Pedeutour  F. COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of der(17;22). Cancer Genet Cytogenet 2006;168155- 157
PubMed
O'Brien  KP, Seroussi  E, Dal Cin  P.  et al.  Various regions within the α-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998;23187- 193
PubMed
Wang  J, Hisaoka  M, Shimajiri  S, Morimitsu  Y, Hashimoto  H. Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription-polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 1999;8113- 119
PubMed
Wang  J, Morimitsu  Y, Okamoto  S.  et al.  COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans. J Mol Diagn 2000;247- 52
PubMed
Gokden  N, Dehner  LP, Zhu  X, Pfeifer  JD. Dermatofibrosarcoma protuberans of the vulva and groin: detection of COL1A1-PDGFB fusion transcripts by RT-PCR. J Cutan Pathol 2003;30190- 195
PubMed
Saeki  H, Ohmatsu  H, Hoashi  T.  et al.  Dermatofibrosarcoma protuberans with COL1A1 (exon 18)-PDGFB (exon 2) fusion transcript. Br J Dermatol 2003;1481028- 1031
PubMed
Maire  G, Pedeutour  F, Coindre  JM. COL1A1-PDGFB gene fusion demonstrates a common histogenetic origin for dermatofibrosarcoma protuberans and its granular cell variant. Am J Surg Pathol 2002;26932- 937
PubMed
Hsu  SM, Raine  L. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibodies (PAP) procedures. J Histochem Cytochem 1981;29577- 580
PubMed
Limon  J, Dal Cin  P, Sandberg  AA. Application of long-term collagenase disaggregation for the cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet 1986;23305- 313
PubMed
Coindre  JM, Hostein  I, Maire  G.  et al.  Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 2004;203822- 830
PubMed
Rodriguez-Jurado  R, Palacios  C, Duran-McKinster  C.  et al.  Medallion-like dermal dendrocyte hamartoma: a new clinically and histopathologically distinct lesion. J Am Acad Dermatol 2004;51359- 363
PubMed
Ford  AM, Ridge  SA, Cabrera  ME.  et al.  In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 1993;363358- 360
PubMed
Ford  AM, Pombo-de-Oliveira  MS, McCarthy  KP.  et al.  Monoclonal origin of concordant T-cell malignancy in identical twins. Blood 1997;89281- 285
PubMed
Ford  AM, Bennett  CA, Price  CM, Bruin  MC, Van Wering  ER, Greaves  M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S A 1998;954584- 4588
PubMed
Gale  KB, Ford  AM, Repp  R.  et al.  Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997;9413950- 13954
PubMed
Alexander  FE, Patheal  SL, Biondi  A.  et al.  Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001;612542- 2546
PubMed
Lightfoot  TJ, Roman  E. Causes of childhood leukaemia and lymphoma. Toxicol Appl Pharmacol 2004;199104- 117
PubMed

Correspondence

CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 24

Related Content

Customize your page view by dragging & repositioning the boxes below.